C12Y 301/08
Phosphoric triester hydrolases
Official title: Phosphoric triester hydrolases (3.1.8)
C12Y301/08 (Phosphoric triester hydrolases) appears on 49 US grants and 69 published applications in this corpus.
Search patents in C12Y- Granted patents
- 49
- Published applications
- 69
- Assignees
- 49
- Inventors
- 142
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 6 |
| 2013 | 2 | 3 |
| 2014 | 3 | 2 |
| 2015 | 5 | 5 |
| 2016 | 2 | 7 |
| 2017 | 6 | 4 |
| 2018 | 4 | 3 |
| 2019 | 6 | 6 |
| 2020 | 3 | 7 |
| 2021 | 1 | 3 |
| 2022 | 4 | 2 |
| 2023 | 3 | 7 |
| 2024 | 3 | 5 |
| 2025 | 5 | 6 |
| 2026 | 2 | 1 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Pharmaceutical formulations, methods for treating chemical warfare agent exposure, and modified biomolecules14 Jul 2026US 12,680,090 B1Teledyne FLIR Defense, Inc.
- Stabilized mutants of quorum quenching lactonase and use thereof in treatment of pathogens30 Jun 2026US 12,667,106 B2Migal Galilee Research Institute Ltd.
- Polynucleotides encoding APOA-1 fusion polypeptides30 Dec 2025US 12,509,501 B2Theripion, Inc.
- RNase-PON1 fusion polypeptides and related compositions and methods16 Dec 2025US 12,497,604 B2Theripion, Inc.
- APOA-1 fusion polypeptides and related compositions17 Jun 2025US 12,331,102 B2Theripion, Inc.
- Methods for treating acute coronary syndrome using apoa-1 fusion proteins5 Mar 2026US 2026/0062460 A1Theripion, Inc.
- Recombinant plasmid vectors, method for producing enzymes that hydrolyze organophosphate, carbamate, and pyrethroid insecticides, and the formulation of such enzymes as functional components27 Nov 2025US 2025/0361495 A1Biom, LLC
- Random Heteropolymers Preserve Protein Function in Foreign Environments7 Aug 2025US 2025/0250607 A1The Regents of the University of California
- Polynucleotides encoding apoa-1 fusion polypeptides26 Jun 2025US 2025/0206806 A1Theripion, Inc.
- Rnase-pon1 fusion polypeptides and related compositions and methods15 May 2025US 2025/0154484 A1Theripion, Inc.
Most cited
By later US patents
- Compositions and methods for pesticide degradation7US 10,913,940 B2University of Virginia · 2021
- Paraoxonase fusion polypeptides and related compositions and methods5US 12,180,521 B2Theripion, Inc. · 2024
- Isolated PON1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage5US 8,735,124 B2Yeda Research and Development Co. Ltd. · 2014
- Mutated organophosphorus acid anhydrolases and their uses thereof5US 9,587,232 B1The United States of America as represented by the Secretary of the Army · 2017
- Mutated organophosphorus acid anhydrolases and their uses thereof5US 9,617,526 B1The United States of America as represented by the Secretary of the Army · 2017